Atossa to pursue metastatic breast cancer indication; (Z)-endoxifen more than doubled PFS vs tamoxifen (7.2 vs 2.4 mo)

ATOSSA THERAPEUTICS, INC.

Strategic decision to pursue metastatic breast cancer indication for (Z)-endoxifen, citing potentially faster regulatory path.
Median PFS more than doubled to 7.2 months vs 2.4 months for tamoxifen in CDK4/6i-naïve patients.
Also engaging FDA on additional indications: breast cancer prevention and neoadjuvant therapy.
Early data show Ki-67 ≤10% response rate above 85% across doses in neoadjuvant setting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.